| Dr Kristina S Park, PHARMD | |
|
653 Gravois Bluffs Blvd, Fenton, MO 63026-7715 | |
| (636) 349-3007 | |
| Not Available |
| Full Name | Dr Kristina S Park |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 653 Gravois Bluffs Blvd, Fenton, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427677244 | NPI | - | NPPES |
| 602271207 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2012027493 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kristina S Park, PHARMD 653 Gravois Bluffs Blvd, Fenton, MO 63026-7715 Ph: () - | Dr Kristina S Park, PHARMD 653 Gravois Bluffs Blvd, Fenton, MO 63026-7715 Ph: (636) 349-3007 |
News Archive
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.
Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.
Leading private equity firms active in the healthcare industry today announced the formation of the Healthcare Private Equity Association, a Chicago-based, non-profit trade association whose purpose is to support the reputation, knowledge and relationships of the healthcare private equity community.
› Verified 7 days ago
Mr. Robert C Suhovecky, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1210 Sugar Creek Sq, Fenton, MO 63026 Phone: 636-326-5113 | |
Brian James Voss, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 512 Deer Pointe Ct, Fenton, MO 63026 Phone: 314-809-5111 | |
Mark Froidl, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Bowles Ave, Fenton, MO 63026 Phone: 636-343-0754 | |
Dr. Sara K Rumpel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2058 Fenton Logistics Park, Fenton, MO 63026 Phone: 877-273-1777 | |
Mahdee Shawahin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1210 Sugar Creek Sq, Fenton, MO 63026 Phone: 636-326-5113 | |
Dr. Erica Lynn Schaeffer, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 701 Gravois Bluffs Blvd, Fenton, MO 63026 Phone: 636-343-8402 | |
Catherine Bundschuh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Bowles Ave, Fenton, MO 63026 Phone: 636-343-0754 |